Company Overview and News
2018-09-21 seekingalpha - 1
Electric trucks come in all types and sizes - Delivery truck, rubbish truck, milk truck, semi, forklifts, or even a tractor. Some are hybrid and some are fully electric.
ISUZF HINOF HINOY BCCMY RNSDF ISUZY 7205 TSLA PCAR 7202 DDAIF
The truck units of Toyota Motor Corp. and Volkswagen AG have said they will team up on electric vehicle technology and set up a procurement joint venture as part of a broader alliance.
VLKAF HINOF HINOY 7205 TM 7203 TYT TOYOF
NAGOYA – Toyota Motor Corp. has raised its group-wide global production and sales projections for 2018 to record levels, driven by stronger-than-expected sales in China and benefits from lower auto tariffs there, a source close to the matter said Thursday.
HINOF VLKAF HINOY 7205 TM 7203 TYT TOYOF
2018-07-27 japantimes.co.jp - 1
The Renault-Nissan alliance retained their crown as the world’s largest auto seller in the January to June period for a second consecutive year, outselling major rivals Volkswagen AG and Toyota Motor Corp.
VLKAF HINOF HINOY MMTOY 7205 TM 7203 TYT RNO TOYOF 7211 MMTOF
MBM Resources Bhd (July 10, RM2.40) Maintain buy with an unchanged target price of RM3.19: To recap, Hino Motors established its first assembly plant in Malaysia, with 58% holdings, whilse MBM Resources Bhd holds a 42% stake. The plant was completed in 2014 in Sendayan, Negeri Sembilan and has a capacity of 10,000 units per annum.
HINOF HINOY 7205 5983
Traditional automakers have faced increasing pressure in recent years from changed driving habits, the swift development of technology and emerging rivals from Silicon Valley.
HINOF HINOY 7205 NYTAB GM
U.S. customers have recently shown a distinct shift in the preference for trucks and sports utility vehicles (SUVs), shunning the traditional sedans. Automakers have already started to reorient their programs and strategies in response to the new situation, where the demand for conventional compact and midsize cars has declined while increased for SUVs and pickup trucks. The recent decision of General Motors Company (GM - Free Report) to abandon three Cadillac sedans and replacing them with two new ones over the next three and a half years vindicates this trend.
HINOF HYUO HOG WGO HYUD VLKAF HINOY MGA 7205 MG GM HYUP AAP VLKAY
2018-06-20 zacks - 1
Ford Motor Company (F - Free Report) and Volkswagen AG (VLKAY - Free Report) are mulling over forming an alliance on a range of activities, including the development of commercial vehicles, per Reuters. The alliance would aid both the companies to compete effectively in the global market, which is increasingly demanding high-tech and efficient lower-emission vehicles. Thomas Sedran, the head of the German automaker Volkswagen’s strategy division, noted that the two companies have “strong and complementary positions in different commercial vehicle segments already.
VLKAF HINOF HINOY OSK 7205 ALSN VLKAY
FRANKFURT (Reuters) - Volkswagen AG (VOWG_p.DE) and Ford Motor Co (F.N) are talking about jointly developing and building a range of commercial vehicles including vans, the companies confirmed on Tuesday.
VLKAF HINOF NAV HINOY 7205
THE UMW Holdings Bhd-MBM Resources Bhd-Perodua saga continues to sizzle. In the latest development, Med-Bumikar Mara Sdn Bhd said it will oppose the application filed by Majlis Amanah Rakyat (Mara) over the appointments of two additional directors to Med-Bumikar’s board.
HINOF HINOY 7205
Somewhat easing the tension of a trade war, China announced that it will erase the limit on foreign ownership of domestic auto ventures. This will assist foreign automakers to own factories in the country. Notably, this restriction has been in place since 1994, which limits foreign carmakers to own not more than 50% share of any local establishment. China will lift foreign ownership limit for the wider car market by 2022.
HINOF BLT TM BHPBF WDC TYT HOG TOYOF VLKAF HINOY BHP 7205 7203 BBL BHP GM BHPLF AAP VLKAY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET